Brawn Biotech Limited has submitted a regulatory disclosure to BSE Limited regarding an upcoming board meeting. The meeting of the Board of Directors is scheduled to be held on Thursday, 5th November, 2026. The primary agenda item is to consider and approve the un-audited financial results of the Company for the quarter ended September 30, 2026.
The disclosure references a previous communication dated September 28, 2026, regarding the closure of the Trading Window. In accordance with the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the Company shall remain closed until 16th November, 2026. The trading window is scheduled to reopen on 17th November, 2026.